AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Neuroscience

• Publication date

  2013-06-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1523/JNEUROSCI.1165-13.2013PMID 23761903PMCID PMC6618391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.

  2012cited by this paper
• Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease*

  2012cited by this paper
• β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment

  2012cited by this paper
• Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.

  2012cited by this paper
• Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011)

  2012cited by this paper
• O1‐06‐06: Regulation of BACE1 expression by GSK3‐beta and its therapeutic effect on Alzheimer's disease

  2012cited by this paper
• The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease

  2012cited by this paper
• A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

  2012cited by this paper
• P4‐195: Effects of Icarrin on Aβ burden in a mouse model of Alzheimer's disease

  2012cited by this paper
• γ-Secretase Modulator in Alzheimer's Disease: Shifting the End

  2012cited by this paper
• Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

  2012cited by this paper
• Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects.

  2011cited by this paper
• β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic mice

  2011cited by this paper
• Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation

  2011cited by this paper
• Species Independence in Brain Tissue Binding Using Brain Homogenates

  2011cited by this paper
• Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

  2010cited by this paper
• A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates Aβ Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

  2010cited by this paper
• Reduced Sodium Channel Nav1.1 Levels in BACE1-null Mice*

  2010cited by this paper
• Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability.

  2010cited by this paper
• Restoring Blood-Brain Barrier P-Glycoprotein Reduces Brain Amyloid-β in a Mouse Model of Alzheimer's Disease

  2010cited by this paper
• First Demonstration of Cerebrospinal Fluid and Plasma Aβ Lowering with Oral Administration of a β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates

  2009cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Development of a High-Throughput Brain Slice Method for Studying Drug Distribution in the Central Nervous System

  2009cited by this paper
• The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential

  2009cited by this paper
• Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice*

  2007cited by this paper
• Macrocyclic inhibitors of beta-secretase: functional activity in an animal model.

  2006cited by this paper
• Macrocyclic Inhibitors of β-Secretase: Functional Activity in an Animal Model.

  2006cited by this paper
• Control of Peripheral Nerve Myelination by the ß-Secretase BACE1

  2006cited by this paper
• Bace1 modulates myelination in the central and peripheral nervous system

  2006cited by this paper
• Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein.

  2003cited by this paper
• Characterization of amyloid β peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein

  2003cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

  2001cited by this paper
• Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

  2001cited by this paper
• Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

  2001cited by this paper
• The CA1 Region of the Human Hippocampus Is a Hot Spot in Alzheimer's Disease

  2000cited by this paper
• Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

  1999cited by this paper
• Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease.

  1998cited by this paper
• Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

  1996cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper
• Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.

  1992cited by this paper
• Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production

  1992cited by this paper

• Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs

  2024influential citation
• Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice.

  2021cites this paper
• Chronic BACE-1 Inhibitor Administration in TASTPM Mice (APP KM670/671NL and PSEN1 M146V Mutation): An EEG Study

  2020cites this paper
• The L1 cell adhesion molecule affects protein kinase D1 activity in the cerebral cortex in a mouse model of Alzheimer's disease.

  2020cites this paper
• β-secretase inhibitors for Alzheimer’s disease: identification using pharmacoinformatics

  2019cites this paper
• Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice

  2018cites this paper
• Quantitative Analysis of 18F-PF-06684511, a Novel PET Radioligand for Selective β-Secretase 1 Imaging, in Nonhuman Primate Brain

  2018cites this paper
• Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead.

  2018cites this paper
• Animal Models of Alzheimer's Disease

  2017cites this paper
• NUCLEAR RECEPTORS AS THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE

  2017cites this paper
• VHH AGAINST BACE1 INHIBITS BETA‐SECRETASE ACTIVITY IN VITRO AND IN VIVO

  2017cites this paper
• Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study

  2017cites this paper
• Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer’s Disease

  2017cites this paper
• Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease

  2017cites this paper
• Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of &bgr;‐amyloid in APP/tau/PS1 mouse model of Alzheimer's disease

  2017cites this paper
• Evaluation of μPET outcome measures to detect disease modification induced by BACE inhibition in a transgenic mouse model of Alzheimer’s disease

  2017cites this paper
• Therapeutic implication of autophagy in neurodegenerative diseases

  2017cites this paper
• Widespread brain distribution and activity following i.c.v. infusion of anti‐β‐secretase (BACE1) in nonhuman primates

  2017cites this paper
• Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D.

  2017cites this paper
• AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

  2016influential citation
• Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.

  2016cites this paper
• Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor protein‐specific antibodies

  2016cites this paper
• The Use of Operant Tasks to Assess Cognition in Persons with Alzheimer’s Disease

  2016influential citation
• Novel Therapeutic Strategies for Dementia.

  2016cites this paper
• AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

  2016cites this paper
• Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors

  2015cites this paper
• Alzheimer’s Disease and Mechanism-Based Attempts to Enhance Cognition

  2015cites this paper
• Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery.

  2015cites this paper
• Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β‐amyloid levels in the CNS

  2015cites this paper
• Melatonin regulates the transcription of βAPP‐cleaving secretases mediated through melatonin receptors in human neuroblastoma SH‐SY5Y cells

  2015cites this paper
• Camelid heavy chain only antibody fragment domain against β‐site of amyloid precursor protein cleaving enzyme 1 inhibits β‐secretase activity in vitro and in vivo

  2015cites this paper
• Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice

  2015cites this paper
• Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches

  2015cites this paper
• Enhancement of sAPPα as a Therapeutic Strategy for Alzheimer’s and Other Neurodegenerative Diseases

  2015cites this paper
• Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.

  2015cites this paper
• In Silico Design of BACE1 Inhibitor for Alzheimer's Disease by Traditional Chinese Medicine

  2014cites this paper
• Ablation of MMP9 Gene Ameliorates Paracellular Permeability and Fibrinogen–Amyloid Beta Complex Formation during Hyperhomocysteinemia

  2014cites this paper
• Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.

  2014cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• Multifunctional Effects of Mangosteen Pericarp on Cognition in C57BL/6J and Triple Transgenic Alzheimer's Mice

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

  2014cites this paper
• Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases

  2013cites this paper
• Modeling of age-dependent amyloid accumulation and γ-secretase inhibition of soluble and insoluble Aβ in a transgenic mouse model of amyloid deposition

  2013cites this paper
• Can BACE1 Inhibition Mitigate Early Axonal Pathology in Neurological Diseases?

  2013cites this paper
• Degenerative Neurological and Neuromuscular Disease Dovepress Critical Analysis of the Use of Β-site Amyloid Precursor Protein-cleaving Enzyme 1 Inhibitors in the Treatment of Alzheimer's Disease

  year unknowncites this paper